论文部分内容阅读
目的观察瑞舒伐他汀与洛伐他汀对缺血性心肌病患者心率变异性的影响。方法选取缺血性心肌病患者100例,随机分为瑞舒伐他汀组(A组)50例和洛伐他汀组(B组)50例。A组在常规治疗缺血性心肌病中应用瑞舒伐他汀,B组在常规治疗缺血性心肌病中应用洛伐他汀。观察两组治疗前及治疗后30d心率变异性HRV(SDNN,SDANN,RMSSD,PNN50)的变化。结果 A,B两组患者在治疗后HRV均有不同程度的改善(P<0.05),组间比较,A组患者SDNN,SDANN均较B组有明显改善(P<0.05)。结论瑞舒伐他汀与洛伐他汀均可明显改善缺血性心肌病患者心率,瑞舒伐他汀疗效优于洛伐他汀。
Objective To observe the effect of rosuvastatin and lovastatin on heart rate variability in patients with ischemic cardiomyopathy. Methods 100 patients with ischemic cardiomyopathy were randomly divided into 50 cases of rosuvastatin group (group A) and 50 cases of lovastatin group (group B). Group A received rosuvastatin in routine treatment of ischemic cardiomyopathy and group B received lovastatin in routine treatment of ischemic cardiomyopathy. The changes of heart rate variability HRV (SDNN, SDANN, RMSSD, PNN50) before and 30 days after treatment were observed in both groups. Results The HRV in both groups A and B improved to some extent after treatment (P <0.05). Compared between groups, SDNN and SDANN in group A were significantly improved than those in group B (P <0.05). Conclusion Both rosuvastatin and lovastatin can significantly improve heart rate in patients with ischemic cardiomyopathy, and rosuvastatin is better than lovastatin.